The olmesartan recall now covers 3,744 bottles of a prescription blood pressure pill across the United States, after the US Food and Drug Administration (FDA) classified the action as a Class II recall on 26 October 2026. The pills are a three-in-one combination of olmesartan medoxomil, amlodipine and hydrochlorothiazide, and they were pulled by Macleods Pharma USA after the tablets failed a laboratory test that checks whether a pill releases its medicine properly. Only two specific lots are affected, and the brand-name version of the drug is not part of the recall. If you take this combination pill, the lot number and NDC printed on your bottle are what decide whether the recall applies to you. Searches for "olmesartan" surged this week as the recall news spread.
Which Lots Are Affected in the Olmesartan Recall?
Only two lots of the generic three-in-one tablet are recalled, both made from the same bulk batch and both carrying a May 31, 2027 expiry date. The 30-count bottles are lot 12251163A, NDC 33342-246-07 — 3,528 bottles. The 90-count bottles are lot 12251163B, NDC 33342-246-10 — 216 bottles. Together that is 3,744 bottles, distributed nationwide in the United States between 21 November 2025 and 27 April 2026. The failed test was found in the 90-count batch; the 30-count batch was recalled as a precaution because it came from the same bulk batch, 12251163.
To check your own medicine, look for the lot number and the NDC on the label of the bottle your pharmacy gave you. Both must match one of the two rows above for the recall to apply. If your bottle's lot and NDC do not match either one, then on the information published so far, this recall does not apply to your medicine. The number of tablets your pharmacy dispensed to you may differ from the manufacturer's bottle size, so match the lot and NDC, not the tablet count.
Why the Olmesartan Recall Happened: A Failed Dissolution Test
The reason for the recall is a failed dissolution specification. A dissolution test is the laboratory check that a tablet breaks apart and releases its active ingredient at the right rate once swallowed. During nine-month stability testing of the 90-count batch, the olmesartan in the tablets dissolved at a mean of 79% across 24 tablets, against a requirement of not less than 80%. The company described the olmesartan result as "marginal low". The other two ingredients in the same tablets, amlodipine and hydrochlorothiazide, met their dissolution specifications, and all individual units met the unit-level criteria for the test stage.
What that means in practice is that the affected tablets may release their olmesartan more slowly or less completely than intended, which could temporarily weaken blood-pressure control. This is a quality failure, not a contamination finding: nothing in the published record says the tablets contain a wrong ingredient or a harmful substance. Macleods' own health hazard assessment found no adverse-event reports or spontaneous safety reports for the affected batch, and the company concluded that the product was "not expected to pose a risk to consumer safety under the labeled conditions."
Macleods began the voluntary recall on 7 October 2026, and the FDA classified it as Class II on 26 October 2026. The recall is being carried out at the retail and pharmacy level as a precautionary measure, with the FDA's knowledge. The story reached a wider audience in early November, when USA Today reported the recall on 2 November and local stations followed on 3 November, which is when searches for the drug's name surged.
What to Do If Your Blood Pressure Pills Are in the Olmesartan Recall
First, check the lot number and NDC on your bottle against the two affected lots. If neither matches, nothing in this recall applies to your medicine and there is nothing to do. If one does match, contact your pharmacist or your doctor and follow the recall instructions they give you. They can arrange a replacement supply from an unaffected lot, which is the normal route for a pharmacy-level recall like this one.
Do not stop taking your blood pressure medicine, and do not change your dose, without speaking to a pharmacist or a clinician first. Stopping a blood pressure pill abruptly can be riskier than the recall itself, and the FDA's general guidance for a Class II recall is that patients can generally keep taking the medicine unless the recalling company or the FDA directs otherwise. The documented concern with these tablets is weaker blood-pressure control, not poisoning, and the effect is described as temporary and medically reversible.
Brand-Name Tribenzor Is Not Part of the Olmesartan Recall
The recalled tablets are the generic version of the brand-name drug Tribenzor, which combines the same three ingredients at the same strengths: olmesartan medoxomil 40 mg, amlodipine 10 mg and hydrochlorothiazide 12.5 mg. Brand-name Tribenzor itself is not included in this recall. That distinction matters because the two products share the same active ingredients and the same dose, so a patient who only knows the drug by its ingredients could easily assume their medicine is affected when it is not. The check is the manufacturer and the lot: this recall covers only Macleods' generic tablets in the two lots listed above.
What a Class II Recall Means
The FDA uses three recall classifications to describe the possible health consequences of a faulty product. A Class II recall, the middle tier, means that use of the product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. It sits below Class I, which is used when there is a reasonable probability of serious harm or death, and above Class III, which is used when harm is not likely. The Class II label here fits what the company reported: a small shortfall on a laboratory release test, no adverse events, and a possible temporary dip in blood-pressure control rather than a safety emergency.
The Olmesartan Recall Follows a Run of Blood Pressure Drug Recalls
This is not the first blood pressure medicine to be pulled this autumn. In September 2026, Inventia Healthcare recalled 13,567 bottles of 25 mg chlorthalidone tablets after the same kind of dissolution test failure, and in October 2026 more than 21,000 bottles of a separate combination blood pressure pill were recalled. The pattern points to closer scrutiny of how oral tablets are manufactured and tested, rather than to a problem with one company. Other recent recalls covered on Worldlession include GLP-1 injections recalled nationwide over a sterility concern and Kayem Foods' recall of 1.58 million pounds of meat over a temperature risk.
The practical lesson from the olmesartan recall is a small one, and it is the same lesson the FDA's own guidance gives: keep the bottle, read the lot number, and ask your pharmacist if it matches. A recall that covers two lots out of a whole market is designed to be checked in a minute, not worried about for a week — and for the large majority of people taking this combination pill, the answer will be that their bottle is not one of the 3,744.
Sources: International Business Times; Parade; PrimeTimer; The Healthy; USA Today (2 November 2026); WCVB; US Food and Drug Administration enforcement report; California State Board of Pharmacy notice.